The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis.

Marcus R, Wang O, Satterwhite J, Mitlak B

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research1 Jan 2003Cited by 145 (Europe PMC)

PMID12510801DOI10.1359/jbmr.2003.18.1.18PepBankPUB-12510801

Source link PubMedAsk about this study

Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

3 results from studies that gave the peptide. 3 results from people.

01HumanObservational studyEfficacy outcome
In women with osteoporosis and the lowest reported T scores, teriparatide significantly reduced vertebral fracture risk versus placebo.
In plain wordsIn women with the lowest reported bone density scores, teriparatide reduced vertebral fracture risk compared with placebo.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseVertebral fracture risk in lowest T-score subgroup
Study
n: not reported in source
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · Median 19 monthsAs given in this study (human).
Source sentences
Summary
Teriparatide treatment significantly decreased vertebral fracture risk in patients with a vertebral bone mineral density T score of less than -33 or a score between -2.1 and -3.3 (p < 0.001 and p = 0.027, respectively) and showed a trend toward reduced fracture risk in the group with a T score great…
1 context sentence(design, population, supporting numbers)
Summary · context
Using the same cohort, the current study evaluated the relationship between these therapeutic effects and the patient's baseline age, vertebral bone mineral density, and prevalent vertebral fractures.
Report a problemFND-1251080105
02HumanObservational studyEfficacy outcome
In women with osteoporosis and the middle reported T-score range, teriparatide significantly reduced vertebral fracture risk versus placebo.
In plain wordsIn women with the middle reported bone density range, teriparatide reduced vertebral fracture risk compared with placebo.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseVertebral fracture risk in middle T-score subgroup
Study
n: not reported in source
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · Median 19 monthsAs given in this study (human).
Source sentences
Summary
Teriparatide treatment significantly decreased vertebral fracture risk in patients with a vertebral bone mineral density T score of less than -33 or a score between -2.1 and -3.3 (p < 0.001 and p = 0.027, respectively) and showed a trend toward reduced fracture risk in the group with a T score great…
1 context sentence(design, population, supporting numbers)
Summary · context
Using the same cohort, the current study evaluated the relationship between these therapeutic effects and the patient's baseline age, vertebral bone mineral density, and prevalent vertebral fractures.
Report a problemFND-1251080106
03HumanObservational studyEfficacy outcome
In women with osteoporosis and the highest reported T scores, teriparatide showed a nonsignificant trend toward lower vertebral fracture risk.
In plain wordsIn women with the highest reported bone density scores, teriparatide showed a nonsignificant fracture risk reduction compared with placebo.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeVertebral fracture risk in highest T-score subgroup
Study
n: not reported in source
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · Median 19 monthsAs given in this study (human).
Source sentences
Summary
Teriparatide treatment significantly decreased vertebral fracture risk in patients with a vertebral bone mineral density T score of less than -33 or a score between -2.1 and -3.3 (p < 0.001 and p = 0.027, respectively) and showed a trend toward reduced fracture risk in the group with a T score great…
1 context sentence(design, population, supporting numbers)
Summary · context
Using the same cohort, the current study evaluated the relationship between these therapeutic effects and the patient's baseline age, vertebral bone mineral density, and prevalent vertebral fractures.
Report a problemFND-1251080107

Studies that did not test the peptide alone5

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

04HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyEfficacy outcome
In women with osteoporosis, teriparatide increased vertebral bone mineral density more in older women than younger women.
In plain wordsIn women with osteoporosis, teriparatide increased vertebral bone density more in older women than younger women.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseVertebral bone mineral density response by age
Study
n: not reported in source
Comparator
Younger women
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
In women over 65 years of age, treatment resulted in a greater increase in vertebral bone mineral density than in younger women (treatment-by-age interaction, p = 0.037), but baseline age had no effect on the relative risk reduction for vertebral fractures (treatment-by-age interaction, p = 0.558).
1 context sentence(design, population, supporting numbers)
Summary · context
Using the same cohort, the current study evaluated the relationship between these therapeutic effects and the patient's baseline age, vertebral bone mineral density, and prevalent vertebral fractures.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1251080101
05HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyEfficacy outcome
In women with osteoporosis, baseline age did not modify the relative vertebral fracture risk reduction with teriparatide.
In plain wordsIn women with osteoporosis, teriparatide reduced vertebral fracture risk similarly across ages.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeVertebral fracture risk reduction by age
Study
n: not reported in source
Comparator
Other baseline ages
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
In women over 65 years of age, treatment resulted in a greater increase in vertebral bone mineral density than in younger women (treatment-by-age interaction, p = 0.037), but baseline age had no effect on the relative risk reduction for vertebral fractures (treatment-by-age interaction, p = 0.558).
1 context sentence(design, population, supporting numbers)
Summary · context
Using the same cohort, the current study evaluated the relationship between these therapeutic effects and the patient's baseline age, vertebral bone mineral density, and prevalent vertebral fractures.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1251080102
06HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyEfficacy outcome
In women with osteoporosis, teriparatide effects on vertebral fracture relative risk did not differ significantly across baseline bone density tertiles.
In plain wordsIn women with osteoporosis, teriparatide effects on vertebral fracture risk were similar across baseline bone density groups.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeVertebral fracture relative risk by baseline BMD
Study
n: not reported in source
Comparator
Other bone mineral density tertiles
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
When compared across bone mineral density tertiles, the effects of teriparatide on the relative risk for developing new vertebral fractures and increase in vertebral bone mineral density did not differ significantly (p = 0.817 and p = 0.615, respectively).
1 context sentence(design, population, supporting numbers)
Summary · context
Using the same cohort, the current study evaluated the relationship between these therapeutic effects and the patient's baseline age, vertebral bone mineral density, and prevalent vertebral fractures.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1251080103
07HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyEfficacy outcome
In women with osteoporosis, teriparatide effects on vertebral bone density did not differ significantly across baseline bone density tertiles.
In plain wordsIn women with osteoporosis, teriparatide increased vertebral bone density similarly across baseline bone density groups.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeVertebral BMD increase by baseline BMD
Study
n: not reported in source
Comparator
Other bone mineral density tertiles
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
When compared across bone mineral density tertiles, the effects of teriparatide on the relative risk for developing new vertebral fractures and increase in vertebral bone mineral density did not differ significantly (p = 0.817 and p = 0.615, respectively).
1 context sentence(design, population, supporting numbers)
Summary · context
Using the same cohort, the current study evaluated the relationship between these therapeutic effects and the patient's baseline age, vertebral bone mineral density, and prevalent vertebral fractures.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1251080104
08HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyEfficacy outcome
In women with osteoporosis, teriparatide effects on vertebral fracture relative risk were similar across prevalent fracture subgroups.
In plain wordsIn women with osteoporosis, teriparatide effects on vertebral fracture risk were similar across groups with different prior fracture burdens.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeVertebral fracture relative risk by prevalent fracture subgroup
Study
n: not reported in source
Comparator
Other prevalent vertebral fracture subgroups
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
When compared within prevalent vertebral fracture subgroups, the effects of teriparatide on the relative risk for developing new vertebral fractures were similar.
1 context sentence(design, population, supporting numbers)
Summary · context
Using the same cohort, the current study evaluated the relationship between these therapeutic effects and the patient's baseline age, vertebral bone mineral density, and prevalent vertebral fractures.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1251080108

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.